Compare SBGI & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | BBOT |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1995 | N/A |
| Metric | SBGI | BBOT |
|---|---|---|
| Price | $16.44 | $12.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $21.00 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 455.0K | 178.5K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,337,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.89 | $8.50 |
| 52 Week High | $18.36 | $14.87 |
| Indicator | SBGI | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | N/A |
| Support Level | $14.25 | N/A |
| Resistance Level | $17.21 | N/A |
| Average True Range (ATR) | 0.63 | 0.00 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 74.29 | 0.00 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.